SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: 777 Captain who wrote (10095)6/25/1998 8:35:00 PM
From: blankmind  Respond to of 23519
 
- Someone mentioned that VVUS could mothball the old plant & move all production in to the high volume/ low cost new plant.

-- Does anyone know if this is CEO Leland's strategy?

Thanks.



To: 777 Captain who wrote (10095)6/26/1998 9:21:00 AM
From: Diamondcutter  Respond to of 23519
 
<<Allowance for sales returns?>>

A quick glance at their 10K and 10Q doesn't give much info on what % of sales are estimated to be bad. Given that MUSE was covered by most HMOs, I'd guess the % is fairly small. Accts rec were $17m at 3/31 up from $12m at 12/31. They mention that cash may have to be raised for international expansion and this may be by selling the receivables (or debt, stock etc).

diamondcutter



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News